Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection
Brumme, Zabrina La; Tao, Irisb,*; Szeto, Sharonb,*; Brumme, Chanson Ja; Carlson, Jonathan Mc,d; Chan, Dennisonb; Kadie, Carlc; Frahm, Nicolea; Brander, Christiana; Walker, Brucea,e; Heckerman, Davidc; Harrigan, P Richardb,f
From the aPartners AIDS Research Center, Massachusetts General Hospital, Boston, Harvard Medical School, Massachusetts, USA
bBC Centre for Excellence in HIV/AIDS, Vancouver, Canada
cMicrosoft Research, Redmond, Washington, USA
dDepartment of Computer Science, University of Washington, Seattle, Washington, USA
eHoward Hughes Medical Institute, Chevy Chase, Maryland, USA
fDivision of AIDS, University of British Columbia, Vancouver, British Columbia, Canada.
* These authors contributed equally to this work.
Received 24 January, 2008
Revised 12 March, 2008
Accepted 18 March, 2008
Correspondence to Zabrina L. Brumme, PhD, Partners AIDS Research Center, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129, USA.
Objective: Selection of specific human leukocyte antigen (HLA)-restricted cytotoxic T-lymphocyte (CTL) escape mutations in key Gag epitopes has been associated with loss of HIV immune control on an individual basis. Here we undertake a population-based identification of HLA-associated polymorphisms in Gag and investigate their relationship with plasma viral load.
Design: Cross-sectional analysis of 567 chronically HIV subtype B-infected, treatment-naive individuals.
Methods: HLA class I-associated Gag substitutions were identified using phylogenetically corrected analysis methods featuring a multivariate adjustment for HLA linkage disequilibrium and a q-value correction for multiple tests. Presence of HLA-associated substitutions and markers of HIV disease status were correlated using Spearman's rank test.
Results: We have created a gene-wide map of HLA class I-associated substitutions in HIV-1 subtype B Gag. This features 111 HLA-associated substitutions occurring at 51 of 500 Gag codons, more than 50% of which occur within published and/or putative HLA-restricted CTL epitopes. A modest inverse correlation was observed between the total number of HLA-associated Gag polymorphic sites within each individual and plasma viral load in chronic untreated infection (R = −0.17, P < 0.0001), supporting the hypothesis that a broad ability to target Gag in vivo contributes to viral control. A modest positive correlation was observed between the proportion of these sites exhibiting HLA-associated substitutions and plasma viral load (R = 0.09, P = 0.03), consistent with a loss of viremia control with the accumulation of CTL escape mutations.
Conclusion: Results contribute to our understanding of immune-driven viral adaptation and suggest that the accumulation of CTL escape mutations in Gag results in clinically detectable consequences at the population level. These data have implications for HIV vaccines.
The human leukocyte antigen (HLA)-restricted cytotoxic T-lymphocyte (CTL) response is a key determinant of immune control of HIV infection [1,2], and recent data suggest that CTL targeting of Gag contributes strongly to this control [3–6]. However, the selection of HLA-restricted CTL escape mutations likely compromises the ability of CTL to suppress HIV replication in the long-term [7–10]. Over the last decade, a number of Gag CTL escape mutations have been identified in cross-sectional and observational studies [7–11]. These, however, have been somewhat biased toward HLA alleles associated with long-term control of HIV infection [11–17], and a population-based, gene-wide identification of HLA-associated polymorphisms across Gag remains to be undertaken. Similarly, although loss of viremia control following CTL escape has been reported for single epitopes on a case-by-case basis [17–19], results appear to be poorly generalizable across all epitopes and HLA restrictions [20,21]. A clear relationship between CTL escape in Gag and HIV disease progression has yet to be demonstrated on a more general level.
Here we identify HLA class I-associated polymorphisms across Gag in a large (N = 567), population-based cohort of chronically infected, treatment-naive individuals harboring predominantly subtype B infections . We use novel statistical approaches correcting for the underlying phylogenetic structure of HIV sequence data  to create an ‘immune escape map’ of HLA-associated polymorphisms in Gag. We then use these defined polymorphisms to explore the relationship between plasma viral load (pVL), CD4 cell count, and mutations selected under active in-vivo immune pressure in Gag.
HLA-associated polymorphisms in Gag were identified in a cross-sectional analysis of 567 antiretroviral naive, chronically infected individuals selected from the British Columbia Highly Active Antiretroviral Therapy (HAART) Observational Medical Evaluation and Research (HOMER) cohort  based on the concomitant availability of a peripheral blood sample for HLA typing and HIV Gag sequence data. HLA-associated polymorphisms in protease, reverse transcriptase, Vpr, and Nef were previously defined in this cohort using consistent methods . CD4 count, pVL, and viral sequences correspond to the latest pretherapy measurement collected within 180 days prior to HAART initiation. Ethical approval was granted by the University of British Columbia-Providence Healthcare Research Ethics Board (UBC-PHC REB). For scientists wishing to investigate HLA-associated polymorphisms in this dataset, HLA–HIV data are available upon request pending application to and approval by the UBC-PHC REB.
Gag and a portion of protease were amplified from extracted plasma HIV RNA by nested reverse transcriptase–PCR using gene-specific primers, and ‘bulk’ sequenced in 5′ and 3′ directions on an ABI 3730 automated sequencer. Data were analyzed using Sequencher (GeneCodes, Ann Arbor, Michigan, USA). Nucleotide mixtures were called if the secondary peak exceeded 25% of the dominant peak height. Sequences were aligned to HIV-1 subtype B reference strain HXB2 (GenBank accession no. K03455) using a modified NAP algorithm . Sequences have been deposited in GenBank (EU241938–242504). HLA class I typing was performed as described .
Identification of human leukocyte antigen-associated polymorphisms
Previous studies  have demonstrated the importance of correcting for the underlying phylogenetic structure of HIV sequence data when identifying sites of HLA-mediated immune selection. To identify HLA-associated polymorphisms in Gag, we therefore used phylogenetically corrected methods described in detail in [22,26], modified to incorporate a correction for linkage disequilibrium between HLA alleles. Briefly, a maximum likelihood phylogenetic tree was constructed from Gag sequences. For each observed amino acid, a likelihood ratio test was used to evaluate whether a model incorporating both phylogenetic structure and HLA-mediated selection pressure (conditional evolution model) explained the data significantly better than a model assuming neutral evolution according to the tree (independent evolution model). The presence or absence of a given HLA allele was correlated with the presence or absence of a given amino acid on a codon-by-codon basis (restricted to HLA–HIV amino acid pairs with a minimum of three actual or expected counts in every cell of the two-by-two contingency table). For every amino acid at each codon, the allele with the strongest association was added to the list of identified associations. Then, individuals expressing this allele were removed and the analysis repeated. This forward-selection procedure was iterated until no HLA allele yielded an association with uncorrected P less than 0.05, thus tending to eliminate spurious associations due to HLA linkage disequilibrium. A q-value statistic, which estimates the false-discovery rate among identified associations, was used to adjust for multiple comparisons [27,28]. Associations with q-value 0.2 or less (indicating a 20% false-discovery rate) are presented; this corresponded to P-values 6.5 × 10−37 <P < 0.0015.
Associations were grouped into two categories based on the direction of the selection pressure. We refer to amino acids enriched in the presence of a particular HLA allele (presumably representing the residue most likely to emerge under CTL-selection pressure) as the ‘escape’ form, and amino acids enriched in the absence of a particular HLA allele (presumably reflecting the ‘wild-type’ residue most likely to reemerge following transmission to an HLA-unmatched individual) as the ‘reversion’ form.
Immune escape maps
HLA-associated polymorphisms in Gag were organized into immune escape maps. If an association fell within three amino acids of a published CTL epitope (defined as all HLA class I-restricted 15-mer or less epitopes listed in the Los Alamos HIV Immunology database as of 7 June 2007 ) or predicted CTL epitope (as identified by Epipred, a published epitope prediction tool available at http://atom.research.microsoft.com/bio/epipred.aspx ), the sequence and HLA restriction of this epitope was indicated. The +/− three amino acid window was chosen to account for putative proteasomal processing escape mutations [31–34]. To provide in-vitro functional support to identified associations, we drew upon an independent dataset of 372 HIV-1 infected individuals screened for CTL-mediated interferon (IFN)-γ responses against a set of 410 overlapping subtype B consensus peptides spanning the whole expressed HIV-1 proteome using an IFN-γ enzyme-linked immunosorbent spot (ELISpot) assay . Fisher's exact test was used to identify HLA alleles significantly associated with IFN-γ production in response to particular peptides, thus supporting the presence of an uncharacterized HLA-restricted CTL epitope within the peptide boundaries.
A 20% false-discovery rate is expected with q-value 0.2 or less [26,27]. Although we attempted to assign as many associations as possible to known or putative CTL epitopes, epitope proximity alone does not guarantee a true-positive result. Furthermore, as associations occurring distant to epitopes may represent compensatory mutations, distant processing mutations, or other factors . Therefore, all identified associations are included on the map.
Human leukocyte antigen-associated substitutions in Gag
A substantial level of amino acid variation was observed in p17 (matrix) and C-terminal proteins (p2/p7/p1/p6), with non-consensus variation at single codons ranging from 0 to 59.6% (interquartile range [IQR] 0.4–11.7%) in p17 and 0 to 57.7% (IQR 0.1–14.3%) in p2/p7/p1/p6 using the cohort (subtype B) consensus as a reference. In contrast, p24 (capsid) was more conserved, with single codon variation ranging from 0 to 42.7% (IQR 0–1.1%). A total of 111 unique HLA-associated polymorphisms were identified with q-value 0.2 or less: these included 36, 42, and 33 associations occurring at 16 (of 132; 12%) codons in p17, 16 (of 231; 7%) codons in p24, and 19 (of 137; 14%) of codons in p2/p7/p1/p6 (Fig. 1). As expected, HLA associations were observed at relatively variable residues, although not exclusively (Fig. 1). Of the 111 observed associations, 50 (45%) represented escape polymorphisms (amino acids enriched in the presence of a specific HLA allele) whereas 61 (55%) represented reversion polymorphisms (those enriched in the absence of a specific HLA allele). Half (55 of 111) of the observed associations were attributable to HLA-B alleles, a fraction consistent with the higher number of unique alleles at the B locus compared to A and C loci.
Gag immune escape map
Of the 111 identified HLA-associated polymorphisms, nearly half (51 of 111; 46%) mapped inside or within three amino acids of a published CTL epitope, whereas an additional 13 (12%) mapped within or near a putative epitope as supported by functional IFN-γ ELISpot data  and/or the presence of an HLA-binding motif  (Fig. 2a). Results confirmed a number of previously identified escape mutations, including the B*57-associated substitution at codon 147 within the B*57-restricted p24 IW9 epitope [32,36], B*57 and B*58-associated substitutions at codons 242 and 248 within the B*57/B*58-restricted p24 TW10 epitope [10,11], B*27-associated substitutions at codons 264 and 268 within the B*27-restricted p24 KK10 epitope [16,17], and B*13-associated substitutions at codons 147, 436, and 437 occurring within or near recently defined B*13-restricted epitopes . We confirmed a number of associations identified in the only other lineage-corrected analysis of Gag to date , including B*07-associated substitutions at codon 357, A*31-associated substitutions at codons 397 and 403, and B*40-associated substitutions at codons 398 and 482. Of interest, no HLA-A*02-associated substitutions were observed in the p17 SL9 (SLYNTVATL) epitope, despite previous reports describing such substitutions at positions 3, 6, and 8 (HXB2 codons 79, 82, and 84) . Substitutions were, however, identified within A*01, A*29, and C*14 epitopes overlapping SL9.
A number of epitopes (including A*01-GY9, C*14-LY8, B*57/B*58-TW10, B*27 KK10, and B*13-RI9) harbored HLA-associations at multiple residues, highlighting cases in which escape involves multiple substitutions. Also of interest are six Gag codons (79, 95, 268, 312, 374, and 403) under diametrically opposed HLA-associated selection pressures at the population level (in which the escape form for one allele represents the reversion form for another, and vice versa). Finally, no significant enrichment for HLA-associated polymorphisms was observed at HLA anchor residues (generally residues 2 and C-terminal with some exceptions [29,37]) compared to other positions within CTL epitopes (P = 0.15). This indicates that abrogation of peptide–HLA binding is not the preferred route of CTL escape in most cases , providing support for the inclusion of HLA-associated polymorphisms into immunogen design .
HLA-associated ‘insertion’ and ‘frameshift’ polymorphisms
Amino acid insertions are commonly observed at the 3′ end of p17, as well as in p6, and may represent a novel mechanism of CTL escape . In a posthoc analysis, six HLA-associated ‘insertion polymorphisms’ were identified. Possession of B*44, A*32, or C*05 was associated with having insertions near the C-terminus of p17 (at codons 119 [B*44] or 125 [A*32 or C*05]), whereas C*07 was associated with insertions at codon 471 in p6. In contrast, possession of A*26 and A*02 were associated with the absence of insertions at codons 119 (p17) and 471 (p6), respectively. None of these associations mapped within three amino acids of a known epitope. In addition, the Gag–Pol ribosomal frameshift occurs within p1, and peptides derived from either p6Gag or p6Pol frames could represent CTL targets [29,39]. Six additional HLA-associated polymorphisms were identified at three p6Pol codons (Fig. 2b). Only the B*53 association at codon 34 was, however, unique to the p6Pol reading frame, and none mapped within or near a known or predicted epitope.
The potential breadth of HLA-mediated anti-Gag selection pressure correlates inversely with plasma viral load
To investigate the extent to which an individual's total potential in-vivo HLA-restricted anti-Gag CTL targeting capacity may contribute to HIV immune control , we investigated the relationship between the total number of HLA-associated polymorphic Gag sites in each subject and clinical markers of HIV disease (pVL and CD4 count) in a cross-sectional analysis. Each subject was assigned a score reflecting the total number of Gag codons at which an HLA association was observed at the population level. For example, Fig. 2 indicates that the A*01, A*02, B*07, B*57, C*05, and C*06 alleles were associated with substitutions at 2, 1, 2, 3, 1, and 1 Gag codons, respectively; a subject with this HLA profile would thus be assigned a score of 10.
A modest yet significant inverse correlation was observed between the total number of HLA-associated sites in Gag and pVL in chronic untreated infection (R = −0.17, P < 0.0001; Fig. 3a), supporting the hypothesis that a broad ability to target Gag contributes to HIV immune control [3–7]. This remained significant after removal of individuals expressing known ‘protective’ alleles B*57, B*27, B*51, or B*13 [12,40]. These trends remained generally consistent when class I loci were examined individually: significant associations were observed between the number of HLA-A (R = −0.10, P = 0.01) and HLA-B (R = −0.11, P = 0.01), but not HLA-C-associated Gag polymorphic sites and pVL. The association between pVL and the total number of polymorphic Gag sites remained significant when individual Gag proteins were examined individually: p17 (R = −0.11, P = 0.008), p24 (R = −0.1, P = 0.03), and p2/p7/p1/p6 (R = −0.13, P = 0.007). Despite statistical significance, the overall magnitude of this effect was small: interpreting the coefficient of determination statistic (R2) indicates that less than 3% of observed population pVL variability is explained by differences in the number of Gag sites under in-vivo HLA-associated selection pressure. Note that no correlation was observed between the number of HLA-associated Gag sites and CD4 count (R = 0.04, P = 0.3; Fig. 3b). Analysis of HLA loci and Gag proteins separately also failed to show a significant association between HLA-associated Gag sites and CD4 cell count (not shown).
The proportion of escaped positions within Gag correlates positively with plasma viral load and inversely with CD4 cell count
Although the clinical consequences of Gag escape have been documented on a case-by-case basis [17–19], the relationship between HLA-associated Gag polymorphisms and pVL has not been investigated on a general level. For each individual, we calculated the ‘proportion of escaped sites’ (i.e. the proportion of sites displaying the specific HLA-associated substitution identified in Fig. 2) and correlated this statistic with pVL (Fig. 4a) and CD4 cell count (Fig. 4b). To use the previous example, an individual with the HLA profile A*01/*02, B*07/*57, C*05/*06, who had escaped at five of their 10 possible sites, was assigned a value of 0.5. Note that values below 0.2 were relatively rare, consistent with a cohort in relatively advanced disease.
A modest yet significant positive correlation was observed between the proportion of escaped sites and higher pVL (R = 0.09, P = 0.03). Analyzing each HLA locus and each Gag protein separately revealed no HLA locus-specific or Gag protein-specific correlations, with the exception of p17, which exhibited a significant positive correlation between proportion of escaped sites and higher pVL (R = 0.09, P = 0.03). A trend toward an inverse correlation was observed between the proportion of escaped Gag codons and lower CD4 cell counts (R = −0.08, P = 0.07). Of interest, this trend was driven by p24, which exhibited a significant inverse correlation between proportion of escaped codons and lower CD4 cell counts (R = −0.11, P = 0.01). Analyzing other Gag proteins as well as HLA loci separately revealed no additional significant correlations between proportion of escaped Gag codons and CD4 count.
The present study represents the largest population-based assessment of HLA-associated imprinting on HIV-1 Gag to date. The systematic determination and mapping of more than 100 HLA-associated Gag polymorphisms in vivo (Fig. 2) provides a complementary analysis with CTL/CD8+ epitope maps available at the Los Alamos HIV database (http://www.hiv.lanl.gov/content/immunology). Results confirm a number of Gag escape mutations previously identified in clade B [10,11,16,17], clade C , and mixed-clade  studies, indicating that despite extreme global sequence diversity, HIV subtypes share at least some common escape pathways.
The cohort was previously used to map sites of HLA-mediated selection in protease, reverse transcriptase, Vpr, and Nef . Despite the fact that Gag (notably p24) and Nef feature high epitope density  and are vigorously targeted by CTL in early infection , the overall proportion of Gag codons exhibiting HLA-associated polymorphisms is substantially lower than Nef (∼10 vs. 40%, respectively) . Instead, the density of HLA-associated polymorphisms in Gag is comparable to Pol  a somewhat less frequently targeted protein with lower epitope density, supporting substantial mutational constraints on Gag despite frequent targeting by CTL .
The lack of identification of A*02 SL9 escape mutations in this study is consistent with low in-vivo selection pressure on this epitope [41,43–45], as well as the observation that SL9 variants are found at comparable frequencies among A*02-positive and negative individuals . Although these observations appear to support the ‘HLA imprinting hypothesis’ (which states that the contemporary HIV consensus reflects adaptation to the most frequently expressed HLA alleles) [46–49], it is important to note that current phylogenetically corrected methods are designed to identify HLA-mediated selection events occurring in the terminal branches of the tree only and thus cannot be used to directly address primordial HIV adaptation to host HLA. The observation that more than 50% of identified associations in Gag (and other proteins ) represent reversion associations, combined with the observation that reversion occurs in many cases after transmission to an HLA-unmatched individual [11,50–52] highlights the ongoing, dynamic viral evolution in response to host selection pressures. Analysis of additional contemporary and historical HIV cohorts will further our understanding of how host-related selection forces have shaped HIV evolution at the population level throughout the course of the epidemic, and how they may do so in the future.
Although assessment of in-vitro CTL responses was not possible due to lack of cryopreserved peripheral blood mononuclear cells (PBMC), we observed a significant inverse correlation between potential in-vivo breadth of the anti-Gag CTL response (conservatively estimated by calculating the total number of polymorphic Gag sites specific to each individual's HLA type) and lower pVL, thus supporting the hypothesis that a broad ability to target Gag contributes to HIV control [3,6]. Alleles at the B locus contributed strongly to this trend, consistent with a dominant influence of HLA-B in mediating HIV control . Estimated breadth of CTL responses against p17 and C-terminal Gag proteins correlated most strongly with pVL, suggesting that targeting of all Gag proteins (not only p24) contribute to immune control.
Although the clinical consequences of single Gag CTL escape mutations have been documented on a case-by-case basis [17–20], the relationship between pVL and the presence of HLA-associated Gag substitutions has not been examined at the population level. We observed a modest yet significant positive correlation between the proportion of escaped positions in Gag and higher pVL, suggesting that the accumulation of escape mutations has measurable consequences for containment of viremia by CTL. Note, however, that the absolute magnitude of the effect was minor: using linear regression, each 10% increase in escaped sites was associated with a 7% increase in pVL. Consistent with an accumulation of CTL escape mutations (and concomitant decline in immune function) over the natural course of infection , we observed an inverse correlation, although not statistically significant, between the proportion of escaped codons in Gag and lower CD4 cell count.
Given the potential use of results such as these to guide the selection of CTL vaccine immunogens, it is important to put the results in context of other HIV proteins. In a previous publication, we identified HLA-associated polymorphisms in protease/reverse transcriptase and Nef and investigated the relationship between these polymorphisms and clinical markers of HIV disease using similar methods . To allow an unbiased comparison of results, we reanalyzed the protease/reverse transcriptase and Nef datasets using the methods described in this study. We observed a weak, marginally significant inverse correlation between the total number of HLA-associated sites in Nef and pVL in chronic untreated infection (R = −0.07, P = 0.04), however, no correlation between pVL and HLA-associated sites in protease/reverse transcriptase and pVL was observed (not shown). These results support the hypothesis that CTL targeting of Gag contributes more to immune control of HIV than CTL targeting of other proteins. With respect to the immune consequences of escape, we observed no significant association between the proportion of escaped sites and pVL in Nef or protease/reverse transcriptase (not shown). Again, this result supports a more substantial consequence of escape in Gag compared to other HIV proteins.
Complex conflicting forces mediate the relationship between escape and clinical progression. In many cases the selected escape variant maintains some HLA binding and/or CTL recognition capacity , whereas in others, de-novo CTL responses may arise against escaped variants , such that the selection of individual mutations may result in only incremental, if any, consequences to viremia control. In addition, Gag escape mutations may come at a substantial cost to viral fitness (as recently demonstrated for the immunodominant B*57 and B*27-restricted TW10 [13,14] and KK10  epitopes, respectively), thus rendering the potential pVL consequences of escape smaller than anticipated. Note, however, that in the present study, the association between Gag escape and lower pVL remained after controlling for B*57 and/or B*27 expression. Furthermore, the fact that the cohort comprises chronically infected individuals may also underestimate the correlation between anti-Gag CTL targeting (and escape) on clinical disease markers, as the residual effects of anti-HIV CTL activity in earlier infection may be difficult to detect in later stages. Other limitations include the use of a single pVL and CD4 measurement to represent the clinical status of each individual, as well as the lack of longitudinal HIV sequence data and comprehensive untreated clinical histories (including seroconversion dates). Finally, the cross-sectional study design prevents us from drawing conclusions regarding whether higher pVL is a cause or consequence of escape. Even acknowledging these limitations, the relatively weak correlation between estimated anti-Gag CTL targeting potential and untreated pVL implies that a successful HIV vaccine would likely have at least an order of magnitude greater effective immune responses than those generally observed in the context of natural infection [56–58]. The recent failure of a phase-II CTL-based vaccine trial [59,60] further underscores the need to better define the correlates of HIV immune protection, and the need to develop strategies for enhancing the appropriate responses through vaccination [56–58].
Nevertheless, the current study provides evidence that the clinical correlates of CTL targeting and escape are more pronounced for Gag when compared to other HIV proteins . These observations further support an important role for CTL targeting of Gag in containment of HIV viremia [3–6,12,61], and provide support for CTL-based vaccine strategies focusing on immunogenic yet mutationally refractive viral regions such as Gag.
The authors wish to thank Theresa Mo and Celia Chui for technical assistance, Brian Wynhoven and Conan Woods for database assistance, Philippa Matthews and Philip Goulder for helping to develop the phylogenetically corrected, HLA linkage-disequilibrium-corrected analysis.
Funding Sources: Z.L.B. is supported by a postdoctoral fellowship from the Canadian Institutes for Health Research (CIHR). D.H., J.C., and C.K. are funded by Microsoft Research. This work has been funded, in part, with Federal funds from the NIH under contract N01-Al-15422 on HLA typing and T cell epitope mapping relative to HIV vaccine design. Sources of support were neither involved in the design and conduct of the study nor were they involved in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the article.
Role of authors: This study was conceived and designed by Z.L.B. and P.R.H. Data acquisition was performed by I.T., S.S., and Z.LB. (HLA and HIV data) as well as C.B., N.F., and B.D.W. (functional ELISpot data). C.J.B., J.M.C., C.K., and D.H. developed analytical methods and analyzed the data. D.C. performed additional data analysis. Initial drafting of the article was performed by Z.L.B. All authors contributed to interpretation of data and critical revision of the manuscript.
1. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103–6110.
2. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650–4655.
3. Zuñiga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, Hernandez A, et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 2006; 80:3122–3125.
4. Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, McCutchan F, et al. CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. J Virol 2007; 81:2440–2448.
5. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, Goepfert PA. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002; 76:2298–2305.
6. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46–53.
7. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991; 354:453–459.
8. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997; 3:205–211.
9. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, Troop M, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A 1997; 94:1890–1895.
10. Goulder PJ, Watkins DI. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 2004; 4:630–640.
11. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004; 10:282–289.
12. Honeyborne I, Prendergast A, Pereyra F, Leslie A, Crawford H, Payne R, et al. Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J Virol 2007; 81:3667–3672.
13. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006; 80:3617–3623.
14. Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, Desouza I, et al. Escape and compensation from early HLA-B57-mediated CTL pressure on HIV-1 Gag alters capsid interactions with cyclophilin A. J Virol 2007; 81:12608–12618.
15. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, et al. Escape from the dominant HLA-B27 restricted CTL response in gag is associated with a dramatic reduction in HIV-1 replication. J Virol 2007; 81:12382–12393.
16. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, Conlon C, et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001; 193:375–386.
17. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997; 3:212–217.
18. Feeney ME, Tang Y, Roosevent KA, Leslie AJ, McIntosh K, Karthas N, et al. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J Virol 2004; 78:8927–8930.
19. Oxenius A, Price DA, Trkola A, Edwards C, Gostick E, Zhang HT, et al. Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T cell responses and decrease in HIV-1-specific CD4+ and CD8+ T cell frequencies. J Infect Dis 2004; 190:713–721.
20. Bailey JR, Williams TM, Siciliano RF, Blankson JN. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med 2006; 203:1357–1369.
21. Iversen AK, Stewart-Jones G, Learn GH, Christie N, Sylvester-Hviid C, Armitage AE, et al. Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nat Immunol 2006; 7:179–189.
22. Brumme ZL, Brumme CJ, Heckerman D, Korber BT, Daniels M, Carlson J, et al. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathol 2007; 3:e94.
23. Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, Kadie C, et al. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 2007; 315:1583–1586.
24. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568–2577.
25. Huang X, Zhang J. Methods for comparing a DNA sequence with a protein sequence. Comput Appl Biosci 1996; 12:497–506.
26. Carlson J, Kadie C, Mallal S, Heckerman D. Leveraging hierarchical population structure in discrete association studies. PLoS ONE 2007; 2:e591.
27. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003; 100:9440–9445.
28. Listgarten J, Heckerman D. Determining the number of nonspurious arcs in a learned DAG model: investigation of a Bayesian and a frequentist approach. In: Proceedings of Twenty Third Conference on Uncertainty in Artificial Intelligence. Vancouver, Canada: UAI Press; July 2007.
29. Korber BTM, Brander C, Haynes BF, Koup R, Moore JP, Walker BD, et al., editors. HIV Molecular Immunology 2006. Los Alamos: Los Alamos National Laboratory, Theoretical Biology and Biophysics; 2007.
30. Heckerman D, Kadie C, Listgarten J. Leveraging information across HLA alleles/supertypes improves epitope prediction. RECOMB 2006; LNBI 3939: 296–308.
31. Yokomaku Y, Miura H, Tomiyama H, Kawana-Tachikawa A, Takiguchi M, Kojima A, et al. Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J Virol 2004; 78:1324–1332.
32. Draenert R, Le Gall S, Pfafferott KJ, Leslie AJ, Chetty P, Brander C, et al. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med 2004; 199:905–915.
33. Milicic A, Price DA, Zimbwa P, Booth BL, Brown HL, Easterbrook PJ, et al. CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. J Immunol 2005; 175:4618–4626.
34. Nielsen M, Lundegaard C, Lund O, Kesmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 2005; 57:33–41.
35. Frahm N, Korber BT, Adams CM, Szinger JJ, Draenert R, Addo MM, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004; 78:2187–2200.
36. Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, O'Sullivan KM, et al. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 2005; 79:13239–13249.
37. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213–219.
38. Brander C, Frahm N, Walker BD. The challenges of host and viral diversity in HIV vaccine design. Curr Opin Immunol 2006; 18:430–437.
39. Cao J, McNevin J, McSweyn M, Liu Y, Mullins JI, McElrath MJ. Novel CTL escape by a three amino acid insertion in HIV-1 p6Pol and p6Gag late domain associated with drug resistance. J Virol 2008; 82:495–502.
40. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54:535–551.
41. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, et al. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T cell response against HIV-1. PLoS Med 2006; 3:e403.
42. Altfeld M, Allen TM. Hitting HIV where it hurts: an alternative approach to HIV vaccine design. Trends Immunol 2006; 27:504–510.
43. Brander C, Hartman KE, Trocha AK, Jones NG, Johnson RP, Korber B, et al. Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J Clin Invest 1998; 101:2559–2566.
44. Goulder PJ, Sewell AK, Lalloo DG, Price DA, Whelan JA, Evans J, et al. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J Exp Med 1997; 185:1423–1433.
45. Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, Eldridge RL, et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 2001; 193:181–194.
46. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA, et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002; 296:1439–1443.
47. Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, Sango K, et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2006; 7:173–178.
48. Brander C, Walker BD. Gradual adaptation of HIV to human host populations: good or bad news? Nat Med 2003; 9:1359–1362.
49. Leslie A, Kavanagh D, Honeyborne I, Pfafferott K, Edwards C, Pillay T, et al. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med 2005; 201:891–902.
50. Friedrich TC, Dodds EJ, Yant LJ, Vojnov L, Rudersdorf R, Cullen C, et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med 2004; 10:275–281.
51. Allen TM, Altfeld M, Yu XG, O'Sullivan KM, Lichterfeld M, LeGall S, et al. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol 2004; 78:7069–7078.
52. Li B, Gladden AD, Altfeld M, Kaldor JM, Cooper DA, Kelleher AD, et al. Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J Virol 2007; 81:193–201.
53. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004; 432:769–775.
54. Turnbull EL, Lopes AR, Jones NA, Cornforth D, Newton P, Aldam D, et al. HIV-1 epitope-specific CD8+ T-cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently. J Immunol 2006; 176:6130–6146.
55. Allen TM, Yu XG, Kalife ET, Reyor LL, Lichterfeld M, John M, et al. De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol 2005; 79:12952–12960.
56. Letvin NL. Correlates of immune protection and the development of a human immunodeficiency virus vaccine. Immunity 2007; 27:366–369.
57. Yang OO. Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes. AIDS 2008; 22:325–331.
58. Johnston MI, Fauci AS. An HIV vaccine – evolving concepts. N Engl J Med 2007; 356:2073–2081.
59. HIV vaccine failure prompts Merck to halt trial. Nature 2007; 449:390.
60. Sekaly RP. The failed HIV Merck Vaccine Study: a step back or a launching point for future vaccine development? J Exp Med 2008; 205:7–12.
61. Streeck H, Lichterfeld M, Alter G, Meier A, Teigen N, Yassine-Diab B, et al. Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. J Virol 2007; 81:7725–7731.
cytotoxic T-lymphocyte escape; HIV-1; human leukocyte antigen class I; plasma viral load; viral evolution
© 2008 Lippincott Williams & Wilkins, Inc.
Highlight selected keywords in the article text.